Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Capital Expenditures: 2016-2025

Historic Capital Expenditures for Akebia Therapeutics (AKBA) over the last 7 years, with Sep 2025 value amounting to $77,000.

  • Akebia Therapeutics' Capital Expenditures rose 3750.00% to $77,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $223,000, marking a year-over-year increase of 9.31%. This contributed to the annual value of $33,000 for FY2024, which is N/A change from last year.
  • Akebia Therapeutics' Capital Expenditures amounted to $77,000 in Q3 2025, which was down 38.89% from $126,000 recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Capital Expenditures high stood at $126,000 for Q2 2025, and its period low was $2,000 during Q3 2024.
  • Its 2-year average for Capital Expenditures is $42,333, with a median of $23,500 in 2024.
  • Data for Akebia Therapeutics' Capital Expenditures shows a peak YoY skyrocketed of 3,750.00% (in 2025) over the last 5 years.
  • Over the past 4 years, Akebia Therapeutics' Capital Expenditures (Quarterly) stood at $59,000 in 2021, then surged by 93.22% to $114,000 in 2022, then reached $2,000 in 2024, then soared by 3,750.00% to $77,000 in 2025.
  • Its Capital Expenditures was $77,000 in Q3 2025, compared to $126,000 in Q2 2025 and $18,000 in Q1 2025.